How Ketamine Spawned a $1.7 Billion J&J Blockbuster Drug
🤖AI Özeti
Spravato, a nasal spray derived from ketamine and developed by Johnson & Johnson, has transformed from a seemingly improbable treatment to a billion-dollar success. Initially challenged by delivery issues and regulatory hurdles, it has now become a key player in the evolving landscape of depression treatment. This shift highlights the growing acceptance of innovative therapies in mental health care.
💡AI Analizi
📚Bağlam ve Tarihsel Perspektif
Spravato's journey illustrates the complexities of bringing a new drug to market, especially one that is derived from a substance like ketamine, which has a controversial history. The drug's approval and subsequent success may encourage more pharmaceutical companies to explore unconventional treatments for mental health disorders.
This article is for informational purposes only and does not constitute medical advice. Consult a healthcare professional for personal medical guidance.
Orijinal Kaynak
Tam teknik rapor ve canlı veriler için yayıncının web sitesini ziyaret edin.
Kaynağı Görüntüleİlgili Haberler
Tümünü Gör
NewsAI Mobil Uygulamaları
Her yerde okuyun. iOS ve Android için ödüllü uygulamalarımızı indirin.